Sodium oligomannate: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 23: | Line 23: | ||
{{pharmacology-stub}} | {{pharmacology-stub}} | ||
{{No image}} | |||
__NOINDEX__ | |||
Latest revision as of 00:14, 18 March 2025
Sodium oligomannate is a drug used for the treatment of Alzheimer's disease. It is a marine-derived oligosaccharide, specifically derived from seaweed. Sodium oligomannate was approved for medical use in China in 2019, making it the first new drug approved for Alzheimer's disease in China in 17 years.
Mechanism of Action[edit]
Sodium oligomannate works by remodelling the gut microbiota in patients with Alzheimer's disease. This remodelling process reduces the levels of amino acid metabolites in the blood, which in turn inhibits the abnormal activation of the innate immune system in the brain. This process reduces neuroinflammation and reverses cognitive impairment.
Clinical Trials[edit]
The approval of sodium oligomannate was based on the results of a phase 3 clinical trial. The trial involved 818 patients with mild to moderate Alzheimer's disease. The results showed that sodium oligomannate significantly improved cognitive function in patients with Alzheimer's disease after 9 months of treatment.
Side Effects[edit]
The most common side effects of sodium oligomannate include nausea, diarrhea, and dizziness. These side effects are generally mild and temporary.
Future Research[edit]
Further research is needed to confirm the long-term effects and safety of sodium oligomannate. In addition, research is needed to determine whether sodium oligomannate is effective in patients with severe Alzheimer's disease.
See Also[edit]
